NASDAQ$AVAH

Aveanna Healthcare Holdings Inc · Q4 2025 earnings

Q4 2025 earnings · · Before market open

Briefing

Aveanna Healthcare reported Q4 2025 revenue of $662.5M with GAAP diluted EPS of $0.80 and adjusted EPS of $0.17.

Revenue increased 27.4% to $662.5M driven by growth across PDS, home health, and medical solutions segments. Adjusted EBITDA rose 54% to $85.0M (12.8% margin). GAAP net income was $178.8M ($0.80 diluted EPS) reflecting non-recurring items; adjusted diluted EPS was $0.17. FY2025 revenue grew 20.2% to $2.43B with free cash flow of $131M.

  • Q4 revenue $662.5M (+27.4% YoY).
  • Q4 Adjusted EBITDA $85M (+54%); margin 12.8%.
  • GAAP diluted EPS $0.80; adjusted diluted EPS $0.17.
  • FY2025 revenue $2.43B (+20.2%); free cash flow $131M.
  • Pending Family First acquisition not in FY2026 guidance.

Headline financials

Total Revenue

$663M

No prior period
EPS (adj)

$0.17

No prior period
Net Income

$179M

No prior period

Revenue & EPS history

Aveanna Healthcare Holdings Inc · Revenue · Quarterly

$663M

Q4 2025
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Forward guidance

Management maintained FY2026 revenue guidance of $2.54–2.56B and Adjusted EBITDA of $318–322M, excluding the pending Family First transaction.

Tailwinds

  • FY2026 revenue guide $2.54–2.56B maintained.
  • Adjusted EBITDA guide $318–322M.
  • Thrive Skilled Pediatric integration complete; M&A capacity improved.
  • FY2025 Adjusted EBITDA $321M (+75% YoY).

Headwinds

  • 14-week Q4 2025 vs 13-week prior year affects comparability.
  • GAAP EPS inflated by non-recurring items vs adjusted $0.17.
  • Family First closing and integration risks not in guide.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 14 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

+2.7%

Avg return

Earnings day

+5.0%

Avg return

5 days after

+8.2%

Avg return

30 days after

56%

9 / 16 earnings

Positive

+32.2%

Q2 2024

Best reaction

-8.6%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+9.4%+12.2%+4.4%
Q4 2025-8.2%-4.3%-2.0%
Q3 2026-6.3%-2.5%+1.1%
Q1 2025+14.1%+21.6%+14.3%
Q3 2024+16.2%+20.6%+11.4%
Q2 2024+32.2%+34.4%+58.0%
Q1 2024+2.5%+6.2%+2.9%
Q3 2023+2.0%+26.2%+75.8%
Q2 2023+3.4%+0.6%-21.0%
Q1 2023+3.8%+5.7%+26.7%
Q3 2022-8.3%-19.4%-13.7%
Q2 2022-8.6%-9.1%-12.9%
Q1 2022-6.5%+5.4%+4.0%
Q3 2021-3.1%-16.5%-25.9%
Q2 2021+2.3%-2.0%-2.9%
Q1 2021-1.8%+0.9%+10.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro